PDCD1 and cancer: Recent clinical trials have demonstrated such antitumor effects, and these antibodies are approved for use for the treatment of several advanced cancers.1,2,3,4,5 However, ICI-related adverse events are observed in patients receiving anti–PD-1 antibodies.